ARTICLE | Top Story
Genzyme ups Renagel guidance
February 26, 2001 8:00 AM UTC
GENZ increased to $120-$130 million from $110-$120 million its 2001 sales estimate for Renagel sevelamer, a phosphate binding agent for dialysis patients. The company said the change was based on a 15...